GenomSys ranks 27th in the Eurostars programme ranking out of 287 eligible applications by SMEs covering all scientific disciplines.
GenomSys will lead the consortium formed by SeqOne, the Institute of Medical Genomics (IMEGEN) and The Pirbright Institute, focusing on the MPEG-G algorithm implementation.
SeqOne focuses on the integration of MPEG-G in the currently available software suite for exome and genome interpretation. The Institute of Medical Genomics is a biomedical company of the Genetics specialized in genetic tests and offers the opportunity to test the efficacy of MPEG-G in the medical genomics field. Pirbright researches and surveils virus diseases of farm animals, and viruses spreading from animals to humans. MPEG-G will be introduced in the analysis pipeline of the Institute, enlarging the use cases of the algorithm to animal science.
A workpackage led by Imegen focuses on the use cases of genome sequencing data analysis and technical specifications of the MEGAPIPELINE products. The MEGAPIPELINE project will be coordinated by Claudio Alberti, CTO at GenomSys.
Here are some positive comments on the MPEG-G Standard and the MEGAPIPELINE Project from the report of the Independent Evaluation Panel, the evaluation reports from three independent experts:
“The number and variety of successfully accomplished R&D projects as well as the experience of the management in developing new and risky products constitute an excellent starting point and background to face the challenges of this project”;
“The product is completely new, a breakthrough in terms of compression performance, data access speed, transport capability and new “digital media like” functionality. MPEG-G introduces in genomics the same innovations that MPEG-2, MP3 and JPEG have provided to TV, audio and still pictures”;
“The project team is composed of different and complementary expertises and should insure a comprehensive and appropriate development of innovative bioinformatics software”,
“The development of libraries and software tools to increase performance of existing platforms for genome analyses and reduce the costs for data storage and transfer has the potential to have a very profitable market”;
“The market size and growth prospects have been well addressed and the forecasted market demand and profitability appear very credible and convincing”;
“The commercialization plans are very concrete and credible. All the participating SMEs have a proven track record in marketing advanced computational platforms and solutions”;
“The proposed solution is innovative and goes beyond the scientific and commercial state-of-the-art in the domain. Its added value for the envisaged applications is very convincingly demonstrated”.
About Eurostars
Founded in 2007, Eurostars is the first European funding and support programme supporting research-performing SMEs in their innovative R&D projects. With its bottom-up approach, it stimulates international collaborative research and innovation projects that will be rapidly commercialised.
Eurostars is co-funded from the national budgets of 36 Eurostars countries and by the European Union through Horizon 2020.
For more information please visit: www.eurostars-eureka.eu
